Nanjing Leads Biolabs (HKG:9887) will present a paper on its phase IIb study of its drug to treat a rare form of lung cancer, LBL-024, at this year's European Society for Medical Oncology annual meeting, according to a Monday filing with the bourse.
The biotech company said it was chosen to present three studies overall at the medical conference, reflecting the importance of its clinical research in treating patients with advanced extrapulmonary neuroendocrine carcinoma.
Shares were down 3% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments